Middle East and Africa Down Syndrome Market Analysis, Demand & Growth Forecast

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT OF DOWN SYNDROME LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: PIPELINE ANALYSIS

4.1 PIPELINE PRODUCTS IMPACT ANALYSIS

4.2 NNI-351

4.3 ASPARAGINASE

4.4 ANVS-401

4.5 QUILLIVANT XR

4.6 TOFACITINIB

4.7 MEMANTINE HYDROCHLORIDE

4.8 NICOTINE

4.9 AEF0217

4.1 ACI-24

5 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: LAWS AND REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF DOWN SYNDROME

6.1.2 RISING DEMAND OF EFFECTIVE THERAPIES

6.1.3 RISING AWARENESS ABOUT THE DISEASE

6.1.4 TECHNOLOGICAL ADVANCEMENTS

6.1.5 INCREASING GOVERNMENT SUPPORT

6.2 RESTRAINTS

6.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT

6.2.2 SIDE EFFECTS ASSOCIATED WITH DOWN SYNDROME TREATMENT THERAPIES

6.2.3 HIGH COST OF DIAGNOSIS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 INCREASING RESEARCH AND DEVELOPMENT

6.3.3 PRESENCE OF PIPELINE THERAPIES

6.3.4 PRESENCE OF REIMBURSEMENT

6.4 CHALLENGES

6.4.1 LACK OF SKILLED PROFFESSIONALS

6.4.2 LONG PROCESS FOR PRODUCT LAUNCH

6.4.3 TRANSFER OF COVID-19 INFECTIONS BY DIAGNOSTIC METHODS

7 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET

7.1 PRICE IMPACT

7.2 IMPACT ON SUPPLY CHAIN

7.3 IMPACT ON DEMAND

7.4 STRATEGIC DECISIONS FOR MANUFACTURERS

7.5 CONCLUSION

8 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY DISEASE TYPE

8.1 OVERVIEW

8.2 TRISOMY 21

8.3 TRANSLOCATION DOWN SYNDROME

8.4 MOSAIC DOWN SYNDROME

9 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY TREATMENT

9.1 OVERVIEW

9.2 DIAGNOSIS

9.2.1 SCREENING TESTS

9.2.1.1 First Trimester

9.2.1.1.1 Blood Test

9.2.1.1.2 Nuchal Translucency Testing

9.2.1.2 Integrated Screening Test

9.2.1.2.1 First Trimester

9.2.1.2.2 Second Trimester

9.2.1.3 The Triple Screen or Quadraple Screen Test

9.2.1.4 Ultrasound

9.2.1.5 Cell Free DNA

9.2.2 DIAGNOSTIC TESTS

9.2.2.1 Chronic Villus Sampling

9.2.2.2 Amniocentesis

9.2.2.3 Precutaneous Umbical Cord Sampling

9.3 THERAPY

9.3.1 EARLY INTERVENTION THERAPY

9.3.1.1 Speech-Language Therapy

9.3.1.2 Physical Therapy

9.3.1.3 Occupational Therapy

9.3.1.4 Others

9.3.2 ASSISTIVE TECHNOLOGY

9.3.2.1 Hearing Aids

9.3.2.2 Glasses

9.3.2.3 Others

9.3.3 SURGERY

9.3.3.1 Atrioventricular Septal Defect (AVSD)

9.3.3.2 Duodenal Atresia

9.3.3.3 Others

9.3.4 OTHERS

10 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITAL

10.3 CLINICS

10.4 HOMECARE SETTING

10.5 OTHERS

11 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL

11.1 OVERVIEW

11.2 DIRECT TENDER

11.3 RETAIL SALES

11.4 OTHERS

12 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY GEOGRAPHY

12.1 MIDDLE EAST & AFRICA

12.1.1 SOUTH AFRICA

12.1.2 SAUDI ARABIA

12.1.3 UAE

12.1.4 ISRAEL

12.1.5 KUWAIT

12.1.6 EGYPT

12.1.7 REST OF MIDDLE EAST & AFRICA

13 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

14 COMPANY PROFILE

14.1 F. HOFFMANN-LA ROCHE LTD

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 PERKINELMER INC.

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 ILLUMINA, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENTS

14.4 THERMO FISHER SCIENTIFIC INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENTS

14.5 MYRIAD GENETICS, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENTS

14.6 ABBOTT

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENTS

14.7 ABNOVA CORPORATION

14.7.1 COMPANY SNAPSHOT

14.7.2 PRODUCT PORTFOLIO

14.7.3 RECENT DEVELOPMENTS

14.8 ASDCLINIC.CO.UK

14.8.1 COMPANY SNAPSHOT

14.8.2 SERVICE PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 ATILABIOSYSTEMS

14.9.1 COMPANY SNAPSHOT

14.9.2 PRODUCT PORTFOLIO

14.9.3 RECENT DEVELOPMENT

14.1 BOSTON CHILDREN'S HOSPITAL

14.10.1 COMPANY SNAPSHOT

14.10.2 SERVICE PORTFOLIO

14.10.3 RECENT DEVELOPMENTS

14.11 BOYS TOWN NATIONAL RESEARCH HOSPITAL

14.11.1 COMPANY SNAPSHOT

14.11.2 SERVICE PORTFOLIO

14.11.3 RECENT DEVELOPMENTS

14.12 CHILDREN'S HOSPITAL COLORADO

14.12.1 COMPANY SNAPSHOT

14.12.2 SERVICE PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 DEMEDITEC DIAGNOSTICS GMBH

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 DOWN SYNDROME CORK

14.14.1 COMPANY SNAPSHOT

14.14.2 SERVICE PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 MAYO CLINIC HEALTH SYSTEM

14.15.1 COMPANY SNAPSHOT

14.15.2 SERVICE PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 NATERA, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 REVENUE ANALYSIS

14.16.3 PRODUCT PORTFOLIO

14.16.4 RECENT DEVELOPMENTS

14.17 NEXT BIOSCIENCES

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENTS

14.18 NOVUS BIOLOGICALS (A SUBSIDIARY OF BIO-TECHNE)

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT

14.19 KID SENSE CHILD DEVELOPMENT CORPORATION PTY LTD

14.19.1 COMPANY SNAPSHOT

14.19.2 SERVICE PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 PHYSIO.CO.UK.

14.20.1 COMPANY SNAPSHOT

14.20.2 SERVICE PORTFOLIO

14.20.3 RECENT DEVELOPMENT

14.21 SYMBOL

14.21.1 COMPANY SNAPSHOT

14.21.2 SERVICE PORTFOLIO

14.21.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: PIPELINE ANALYSIS

TABLE 2 REGULATION IMPOSED BY SEVERAL REGULATORY AGENCIES IN DIFFERENT REGIONS

TABLE 3 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA TRISOMY 21 IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA TRANSLOCATION DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA MOSAIC DOWN SYNDROME IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA INTEGRATED SCREENING TEST IN DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA THERAPY IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA THERAPY IN DOWN SYNDROM MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA HOSPITAL IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA CLINICS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA HOMECARE SETTING IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA THERAPY CENTERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA DIRECT TENDER IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA RETAIL SALES IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA OTHERS IN DOWN SYNDROME MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST & AFRICA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST & AFRICA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 36 MIDDLE EAST & AFRICA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST & AFRICA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST & AFRICA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 43 SOUTH AFRICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 44 SOUTH AFRICA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 45 SOUTH AFRICA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 46 SOUTH AFRICA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 47 SOUTH AFRICA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 48 SOUTH AFRICA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 49 SOUTH AFRICA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 50 SOUTH AFRICA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 51 SOUTH AFRICA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 52 SOUTH AFRICA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 53 SOUTH AFRICA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 54 SOUTH AFRICA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 SOUTH AFRICA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 SAUDI ARABIA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 57 SAUDI ARABIA DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 58 SAUDI ARABIA DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 59 SAUDI ARABIA SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 60 SAUDI ARABIA FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 61 SAUDI ARABIA INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 62 SAUDI ARABIA DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 63 SAUDI ARABIA THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 64 SAUDI ARABIA EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 65 SAUDI ARABIA ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 66 SAUDI ARABIA SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 67 SAUDI ARABIA DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 68 SAUDI ARABIA DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 69 UAE DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 70 UAE DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 71 UAE DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 72 UAE SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 73 UAE FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 74 UAE INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 75 UAE DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 76 UAE THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 77 UAE EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 78 UAE ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 79 UAE SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 80 UAE DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 81 UAE DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 82 ISRAEL DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 83 ISRAEL DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 84 ISRAEL DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 85 ISRAEL SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 86 ISRAEL FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 87 ISRAEL INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 88 ISRAEL DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 89 ISRAEL THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 90 ISRAEL EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 91 ISRAEL ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 92 ISRAEL SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 93 ISRAEL DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 94 ISRAEL DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 95 KUWAIT DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 96 KUWAIT DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 97 KUWAIT DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 98 KUWAIT SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 99 KUWAIT FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 100 KUWAIT INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 101 KUWAIT DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 102 KUWAIT THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 103 KUWAIT EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 104 KUWAIT ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 105 KUWAIT SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 106 KUWAIT DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 107 KUWAIT DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 108 EGYPT DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

TABLE 109 EGYPT DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 110 EGYPT DIAGNOSIS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 111 EGYPT SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 112 EGYPT FIRST TRIMESTER IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 113 EGYPT INTEGRATED SCREENING TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 114 EGYPT DIAGNOSTIC TESTS IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 115 EGYPT THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 116 EGYPT EARLY INTERVENTION THERAPY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 117 EGYPT ASSISTIVE TECHNOLOGY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 118 EGYPT SURGERY IN DOWN SYNDROME MARKET, BY TREATMENT, 2019-2028 (USD MILLION)

TABLE 119 EGYPT DOWN SYNDROME MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 120 EGYPT DOWN SYNDROME MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 121 REST OF MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)

List of Figure

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET : DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: MARKET END USER COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF DOWN SYNDROME AND OTHER RELATED DISORDERS AND RISING DEMAND FOR EFFECTIVE THERAPIES IS DRIVING THE MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 TRISOMY 21 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET IN 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET

FIGURE 15 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020

FIGURE 16 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)

FIGURE 17 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY DISEASE TYPE, CAGR (2020-2028)

FIGURE 18 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 1 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY TREATMENT, 2020

FIGURE 2 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY TREATMENT, 2020-2028 (USD MILLION).

FIGURE 3 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY TREATMENT, CAGR (2020-2028)

FIGURE 4 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 5 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY END USER, 2020

FIGURE 6 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 7 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY END USER, CAGR (2020-2028)

FIGURE 8 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY END USER, LIFELINE CURVE

FIGURE 9 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 10 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 11 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)

FIGURE 12 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 13 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: SNAPSHOT (2020)

FIGURE 14 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2020)

FIGURE 15 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 16 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY COUNTRY (2021 & 2028)

FIGURE 17 MIDDLE EAST & AFRICA DOWN SYNDROME MARKET: BY TREATMENT (2021-2028)

FIGURE 18 MIDDLE EAST AND AFRICA DOWN SYNDROME MARKET: COMPANY SHARE 2020 (%)